Clinical Trial Update: Study of Continuous OSI-906 Dosing [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating continuous dosing of OSI-906 in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• OSI-906 (OSI-906)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED